An anticoagulant reversal agent selectively binds to unfractionated heparin enoxaparin and Factor IXa (Kds 28 17 and 35 UM respectively) over edoxaban rivaroxaban Factor Xa Factor IX thrombin antithrombin and fibrinogen and only weakly binds to an enoxaparin-antithrombin complex and fondaparinux (Kds 690 and 9600 UM respectively) in cell-free assays prevents edoxaban-induced decreases in fibrin diameter in isolated human whole blood at 200 Ug/ml reduces edoxaban- dabigatran- apixaban- rivaroxaban- unfractionated heparin- or enoxaparin-stimulated increases in tail transection-induced blood loss in rats